Balchem Corporation

BCPC

US0576652004

Specialty Chemicals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
139.3 ^USD	+0.55%		-2.94%	-6.38%

Mar. 29	Balchem Corporation Announces Management Changes	CI
Mar. 12	Balchem Insider Sold Shares Worth $840,985, According to a Recent SEC Filing	MT

Balchem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

October 27, 2023 at 07:00 am EDT

Balchem Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 229.95 million compared to USD 244.27 million a year ago. Net income was USD 29.08 million compared to USD 25.25 million a year ago. Diluted earnings per share from continuing operations was USD 0.9 compared to USD 0.78 a year ago.
For the nine months, sales was USD 693.74 million compared to USD 709.83 million a year ago. Net income was USD 81.9 million compared to USD 83.96 million a year ago. Diluted earnings per share from continuing operations was USD 2.52 compared to USD 2.59 a year ago.

Latest news about Balchem Corporation

Balchem Corporation Announces Management Changes	Mar. 29	CI
Balchem Insider Sold Shares Worth $840,985, According to a Recent SEC Filing	Mar. 12	MT
Balchem Insider Sold Shares Worth $1,700,613, According to a Recent SEC Filing	Feb. 23	MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999.	Feb. 16	CI
Balchem Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 16	CI
Transcript : Balchem Corporation, Q4 2023 Earnings Call, Feb 16, 2024	Feb. 16
Balchem's Q4 Adjusted Earnings Rise, Net Sales Fall	Feb. 16	MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q4 Revenue $228.7M	Feb. 16	MT
Earnings Flash (BCPC) BALCHEM CORPORATION Reports Q4 EPS $0.95	Feb. 16	MT
Balchem Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 16	CI
North American Morning Briefing : S&P 500 Seen Grinding to New High; PPI Data in Focus	Feb. 16	DJ
Global stocks at two-year highs, Nikkei skirts record	Feb. 16	RE
Balchem Lifts Dividend to $0.79, Payable Jan. 19 to Holders of Record Dec. 27	Dec. 05	MT
Balchem Corporation Announces Dividend, Payable on January 19, 2024	Dec. 05	CI
HC Wainwright Cuts Price Target on Balchem to $135 From $165, Maintains Buy Rating	23-10-30	MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999.	23-10-27	CI
Transcript : Balchem Corporation, Q3 2023 Earnings Call, Oct 27, 2023	23-10-27
Balchem Q3 Adjusted Earnings Rise, Net Sales Fall	23-10-27	MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q3 Revenue $229.9M	23-10-27	MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q3 EPS $1.04	23-10-27	MT
Balchem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
According to a Recent SEC Filing, Balchem Insider Sold Shares Worth $499,979	23-09-12	MT
Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023	23-09-05	CI
HC Wainwright Adjusts Price Target on Balchem to $165 From $150, Maintains Buy Rating	23-07-31	MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999.	23-07-28	CI

Chart Balchem Corporation

Duration

Period

More charts

Company Profile

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

Sector

Specialty Chemicals

Calendar

2024-05-03 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Balchem Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

139.3 USD

Average target price

154.8 USD

Spread / Average Target

+11.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Specialty Chemicals

	1st Jan change	Capi.
BALCHEM CORPORATION	-6.38%	4.49B
ECOLAB INC.	+11.47%	63.22B
SIKA AG	-3.47%	46.34B
GIVAUDAN SA	+13.72%	39.97B
FUJIFILM HOLDINGS CORPORATION	+17.83%	25.46B
EMS-CHEMIE HOLDING AG	+7.27%	18.68B
CELANESE CORPORATION	-0.57%	17.24B
POSCO FUTURE M CO., LTD.	-21.73%	15.81B
SYMRISE AG	+0.22%	14.9B
ALBEMARLE CORPORATION	-19.10%	13.74B

Other Specialty Chemicals